The total number of records retrieved from this search are 3. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_5425	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-8-5	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5426	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-8-5	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5427	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-8-5	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result35% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520